RU2015127471A - АНТИТЕЛО ПРОТИВ с-МЕТ - Google Patents

АНТИТЕЛО ПРОТИВ с-МЕТ Download PDF

Info

Publication number
RU2015127471A
RU2015127471A RU2015127471A RU2015127471A RU2015127471A RU 2015127471 A RU2015127471 A RU 2015127471A RU 2015127471 A RU2015127471 A RU 2015127471A RU 2015127471 A RU2015127471 A RU 2015127471A RU 2015127471 A RU2015127471 A RU 2015127471A
Authority
RU
Russia
Prior art keywords
antibody
seq
amino acid
acid sequence
functional fragment
Prior art date
Application number
RU2015127471A
Other languages
English (en)
Russian (ru)
Inventor
Лилиан ГЁТШ
Тьерри ВЮРШ
Седрик БЕС
Original Assignee
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2015127471(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Пьер Фабр Медикамент filed Critical Пьер Фабр Медикамент
Publication of RU2015127471A publication Critical patent/RU2015127471A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
RU2015127471A 2008-12-02 2009-12-02 АНТИТЕЛО ПРОТИВ с-МЕТ RU2015127471A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IBPCT/IB2008/055663 2008-12-02
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05
US61/184,502 2009-06-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011124751/10A Division RU2560257C2 (ru) 2008-12-02 2009-12-02 АНТИТЕЛО ПРОТИВ c-Met

Publications (1)

Publication Number Publication Date
RU2015127471A true RU2015127471A (ru) 2018-12-21

Family

ID=41693124

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015127471A RU2015127471A (ru) 2008-12-02 2009-12-02 АНТИТЕЛО ПРОТИВ с-МЕТ
RU2011124751/10A RU2560257C2 (ru) 2008-12-02 2009-12-02 АНТИТЕЛО ПРОТИВ c-Met

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2011124751/10A RU2560257C2 (ru) 2008-12-02 2009-12-02 АНТИТЕЛО ПРОТИВ c-Met

Country Status (38)

Country Link
US (4) US8741290B2 (enExample)
EP (4) EP3431502B1 (enExample)
JP (3) JP5863458B2 (enExample)
KR (1) KR101838299B1 (enExample)
CN (2) CN102227446B (enExample)
AR (1) AR074439A1 (enExample)
AU (3) AU2009328318C1 (enExample)
BR (2) BRPI0923231B8 (enExample)
CA (1) CA2743433C (enExample)
CL (2) CL2011001296A1 (enExample)
CO (1) CO6382139A2 (enExample)
CR (1) CR20110324A (enExample)
CY (2) CY1119172T1 (enExample)
DK (2) DK2370468T3 (enExample)
EC (1) ECSP11011127A (enExample)
ES (3) ES2697098T3 (enExample)
GE (2) GEP20135930B (enExample)
HR (2) HRP20171011T8 (enExample)
HU (3) HUE035047T2 (enExample)
IL (2) IL213273A0 (enExample)
LT (2) LT3135691T (enExample)
MA (1) MA32892B1 (enExample)
MX (2) MX2011005677A (enExample)
MY (2) MY192567A (enExample)
NZ (1) NZ593853A (enExample)
PE (1) PE20120343A1 (enExample)
PH (1) PH12015501515A1 (enExample)
PL (3) PL3135691T3 (enExample)
PT (3) PT3431502T (enExample)
RS (2) RS56204B1 (enExample)
RU (2) RU2015127471A (enExample)
SA (2) SA109300720B1 (enExample)
SG (2) SG171851A1 (enExample)
SI (3) SI2370468T1 (enExample)
TN (1) TN2011000216A1 (enExample)
TW (2) TWI523866B (enExample)
WO (1) WO2010069765A1 (enExample)
ZA (1) ZA201105164B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
WO2012030842A2 (en) 2010-09-03 2012-03-08 Academia Sinica Anti-c-met antibody and methods of use thereof
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
JP6429771B2 (ja) * 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
JP6491642B2 (ja) 2013-04-30 2019-03-27 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ ｍＡｂ２抗Ｍｅｔ抗体
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016149265A1 (en) * 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
ES2896709T3 (es) 2016-02-05 2022-02-25 Helixmith Co Ltd Anticuerpos anti-c-Met y usos de los mismos
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
HUE053332T2 (hu) 2016-05-17 2021-06-28 Abbvie Biotherapeutics Inc Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
EP3833385A4 (en) * 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US20220169706A1 (en) * 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
CN115297889A (zh) 2020-09-01 2022-11-04 荣昌生物制药(烟台)股份有限公司 抗c-Met抗体药物偶联物及其应用
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
BR112023020562A2 (pt) 2021-04-06 2023-12-05 Abbvie Biotherapeutics Inc Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina
BR112023020801A2 (pt) * 2021-04-08 2023-12-12 Byondis Bv Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica
TWI895608B (zh) * 2021-04-29 2025-09-01 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
WO2023173109A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib
KR20260015178A (ko) 2023-05-23 2026-02-02 애브비 매뉴팩처링 매니지먼트 언리미티드 컴퍼니 항-c-met 항체 약물 접합체를 이용한 치료 방법
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
KR20030068205A (ko) * 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법
EP1592713A2 (en) * 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005058965A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
DK1915398T3 (en) * 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
CL2007000851A1 (es) * 2006-03-30 2008-03-14 Novartis Ag Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
EP3757132A1 (en) 2020-12-30
CA2743433A1 (en) 2010-06-24
EP2370468A1 (en) 2011-10-05
AU2009328318B2 (en) 2015-11-05
ES2697098T3 (es) 2019-01-22
SA112331005B1 (ar) 2015-09-13
AU2016200725C1 (en) 2017-10-19
CN103351438B (zh) 2016-04-20
US8729249B2 (en) 2014-05-20
AU2016200725B2 (en) 2017-05-25
GEP20135930B (en) 2013-10-10
RS56204B1 (sr) 2017-11-30
RS58018B1 (sr) 2019-02-28
IL231525A0 (en) 2014-04-30
KR101838299B1 (ko) 2018-03-14
CY1121025T1 (el) 2019-12-11
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
HK1162536A1 (zh) 2012-08-31
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
CO6382139A2 (es) 2012-02-15
IL231525B (en) 2019-07-31
EP3135691B1 (en) 2018-08-15
CR20110324A (es) 2011-07-28
SA109300720B1 (ar) 2013-05-25
BR122019023930B1 (pt) 2021-05-04
WO2010069765A1 (en) 2010-06-24
DK2370468T3 (en) 2017-06-19
ES2827277T3 (es) 2021-05-20
TWI523866B (zh) 2016-03-01
US20130109841A1 (en) 2013-05-02
LT3135691T (lt) 2018-11-12
JP2016117721A (ja) 2016-06-30
NZ593853A (en) 2013-03-28
US20130109840A1 (en) 2013-05-02
EP3431502B1 (en) 2020-07-22
GEP20146207B (en) 2014-12-10
EP3135691A1 (en) 2017-03-01
JP6074018B2 (ja) 2017-02-01
BRPI0923231B8 (pt) 2021-05-25
EP3431502A1 (en) 2019-01-23
SG171851A1 (en) 2011-07-28
HUE040553T2 (hu) 2019-03-28
MY192567A (en) 2022-08-29
CL2011001296A1 (es) 2011-08-26
PT3135691T (pt) 2018-11-27
TW201023892A (en) 2010-07-01
JP6309657B2 (ja) 2018-04-11
AU2017203929B2 (en) 2019-03-28
CY1119172T1 (el) 2018-02-14
US8765128B2 (en) 2014-07-01
ZA201105164B (en) 2012-03-28
HRP20181868T1 (hr) 2019-01-11
KR20110097839A (ko) 2011-08-31
SI2370468T1 (sl) 2017-08-31
SI3431502T1 (sl) 2021-01-29
AU2017203929A1 (en) 2017-07-06
LT2370468T (lt) 2017-07-10
PT2370468T (pt) 2017-07-13
EP2370468B1 (en) 2017-04-05
ECSP11011127A (es) 2011-07-29
CL2014000181A1 (es) 2014-07-25
MA32892B1 (fr) 2011-12-01
PH12015501515A1 (en) 2015-12-14
HUE051288T2 (hu) 2021-03-01
HRP20171011T1 (hr) 2017-09-22
BRPI0923231A2 (pt) 2016-01-26
US8747850B2 (en) 2014-06-10
JP2017099392A (ja) 2017-06-08
CN102227446A (zh) 2011-10-26
SI3135691T1 (sl) 2018-12-31
TWI459964B (zh) 2014-11-11
DK3135691T3 (en) 2018-11-19
HK1190414A1 (zh) 2014-07-04
AU2016200725A1 (en) 2016-02-25
MY185200A (en) 2021-04-30
US20130109844A1 (en) 2013-05-02
JP2012510280A (ja) 2012-05-10
TW201446805A (zh) 2014-12-16
JP5863458B2 (ja) 2016-02-16
BRPI0923231B1 (pt) 2020-04-28
PT3431502T (pt) 2020-10-29
RU2560257C2 (ru) 2015-08-20
AU2009328318A1 (en) 2011-07-28
US20110239316A1 (en) 2011-09-29
CN103351438A (zh) 2013-10-16
PL2370468T3 (pl) 2017-09-29
CN102227446B (zh) 2015-10-21
PL3135691T3 (pl) 2019-02-28
MX2011005677A (es) 2011-06-30
SG187518A1 (en) 2013-02-28
AR074439A1 (es) 2011-01-19
TN2011000216A1 (en) 2012-12-17
HUE035047T2 (en) 2018-05-02
ES2629855T3 (es) 2017-08-16
RU2011124751A (ru) 2013-01-10
PL3431502T3 (pl) 2020-12-28
MX341014B (es) 2016-08-03
CA2743433C (en) 2019-06-11
AU2009328318C1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
RU2011124751A (ru) Антитело против смет
HRP20150887T1 (hr) Nova antitijela koja inhibiraju dimerizaciju c-met te njihova upotreba
RU2451689C2 (ru) Новые антипролиферативные антитела
RU2012145232A (ru) Гуманизированные антитела к cxcr4 для лечения рака
KR102610592B1 (ko) 당화 pd-l1에 특이적인 항체 및 그의 사용 방법
RU2011115559A (ru) Антитела к cxcr4 и их применение для лечения рака
RU2434882C2 (ru) Новые антитела к igf-ir и их применение
RU2017122014A (ru) Антитела к c10orf54 и их применения
JP2010532982A5 (enExample)
RU2012137515A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
CA2777691A1 (en) Monoclonal antibodies to progastrin and their uses
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
JP2013520174A5 (enExample)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
RU2014127438A (ru) Антитела против человеческого csf-1r и их применения
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
IL278574B1 (en) Glycan-interacting compounds and methods of use
JP5376948B2 (ja) 腫瘍細胞活性を調節する方法及び組成物
RU2009117237A (ru) Средство для профилактики/лечения рака
EP2430050A1 (en) Humanized axl antibodies
EP2220121A1 (en) Axl antibodies
RU2012154339A (ru) НОВОЕ АНТИТЕЛО ПРОТИВ c-Met
RU2010145063A (ru) Новые антитела, используемые для лечения рака
EP3243838B1 (en) Humanized monoclonal antibody and uses thereof
RU2012140451A (ru) Композиции и способы для диагностики и лечения опухолей

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20180710